Daily PubMed evidence board
Unravelling the link between inflammatory biomarkers and coronary artery ectasia severity: a systematic review and meta-analysis.
This paper is a systematic review and meta-analysis that pooled 53 studies (about 9,168 people) to examine whether blood markers of inflammation are assoc…
Signal score64Research triage score
CertaintyModerateVerify in full text
PMID42284250Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This paper is a systematic review and meta-analysis that pooled 53 studies (about 9,168 people) to examine whether blood markers of inflammation are associated with coronary artery ectasia (CAE). The authors found that people with CAE had higher levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) than controls. White blood cell ratio measures were higher in CAE than in coronary artery disease (CAD) or non-coronary groups, and lymphocyte counts showed a pattern of highest in non-coronary controls, intermediate in CAE, and lowest in CAD. hs-CRP and lymphocyte levels were positively associated with how severe CAE was, and multivariable analyses reported hs-CRP (OR=1.78) and WBC (OR=1.00) as factors related to CAE. These results suggest inflammation is linked to CAE, but the abstract-level data cannot establish causation or immediate changes to clinical care; full-text review is needed to assess study quality and clinical applicability.
Why it matters
- Coronary artery ectasia (CAE) is an under-recognized coronary abnormality with uncertain pathogenesis; identifying inflammatory biomarkers associated with CAE could inform research into mechanisms, risk stratification, and potential biomarker-guided monitoring.
- The meta-analysis pools data across observational studies (total n reported in abstract = 9,168) and reports consistent elevations in hs-CRP, IL-6, and TNF-α in CAE versus controls, suggesting inflammation may be linked to CAE occurrence and severity-this is directly relevant to clinicians and researchers studying CAD phenotypes and inflammatory contributions to vascular remodeling.
- The finding that hs-CRP and lymphocyte count correlate with CAE severity and that hs-CRP and WBC were associated with CAE in multivariate analysis (abstract reports OR=1.78 for hs-CRP; OR=1.00 for WBC) could guide prioritized confirmatory studies and development of prognostic models, but cannot alone justify practice change without full-text verification and assessment of absolute prognostic impact.
Primary outcomes
- Blood inflammatory biomarker level comparisons (hs-CRP, IL-6, TNF-α, WBC, neutrophils, lymphocytes, monocytes); association with CAE occurrence and CAE severity
Effect summary
Abstract-reported pooled findings: CAE patients had higher hs-CRP, IL-6, and TNF-α compared with controls. WBC-to-neutrophil ratio was higher in CAE versus CAD and non-coronary groups. Lymphocyte counts showed a gradient NCA > CAE > CAD. Monocytes were higher in CAE than CAD but similar to NCA. No significant difference reported for NLR between CAE and CAD. hs-CRP and lymphocytes correlated positively with CAE severity. Multivariate analysis reported hs-CRP (OR=1.78) and WBC (OR=1.00) as associated factors for CAE (as presented in abstract).
Benefit-cost lens
| Quick take | This meta-analysis strengthens an association between inflammatory markers (hs-CRP, IL-6, TNF-α) and CAE occurrence and severity, which may justify targeted research or prospective validation. Translating this into clinical benefit requires data on absolute risk/prognosis changes, incremental predictive value, and costs of measuring/intervening on these markers. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assumes abstract-reported pooled associations reflect underlying observational-study data; full-text may change effect estimates, heterogeneity, and risk-of-bias judgments. No causal inference implied; benefit requires validated interventions tied to biomarker status. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Assessment based on abstract only. Although 53 studies were pooled, the abstract does not report study designs, risk-of-bias domains, heterogeneity metrics, publication bias, or whether included studies were prospective vs retrospective. Multivariate analyses are mentioned but details (covariates, model fit) are not available. Full-text risk-of-bias assessment is required. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review to confirm inclusion criteria, study designs, heterogeneity, absolute effect measures, and subgroup analyses; assessment of clinical utility (predictive performance) and cost of biomarker testing; stakeholder and clinician consultation before any practice change. |
|---|---|
| Equity impact | Unclear from abstract. Potential equity considerations include access to biomarker testing and whether associations vary by demographic or socioeconomic subgroups; full-text subgroup analyses needed. |
| Harms | Not reported in abstract. Individual studies likely observational and biomarker measurement itself has low direct harm, but downstream harms could arise from unvalidated interventions based on biomarkers; full-text check required. |
| Replication | Unknown from abstract-level triage; replication would require re-extraction from included studies or independent re-meta-analysis. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.